LLY GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Lilly(Eli) & Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Did you know?
Profit margin of 31.7% — that's well above average.
Current Price
$955.19
+0.20%GoodMoat Value
$1015.63
6.3% undervaluedProfile
Valuation (TTM)
Market Cap$903.02B
P/E43.75
EV$896.05B
P/B34.03
Shares Out945.38M
P/Sales13.85
Revenue$65.18B
EV/EBITDA33.84
Lilly(Eli) & Company (LLY) Quality Analysis
LLY Profitability
Profitability trend analysis coming soon
LLY Growth
Growth trend analysis coming soon
LLY Financial Health
Financial health indicators coming soon
LLY Quality & Fundamental Analysis
Lilly(Eli) & Company (LLY) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. This quality analysis page evaluates Lilly(Eli) & Company's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Lilly(Eli) & Company has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 31.67% and a return on equity (ROE) of 77.78%. Return on assets (ROA) stands at 18.35%.
The debt-to-equity ratio is 1.60, with a current ratio of 1.58. Operating margin is 40.35%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Lilly(Eli) & Company is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.